Dashboard
Manage Tickers

AKROAkero Therapeutics, Inc.

Nasdaq akerotx.com


$ 24.65 $ 0.33 (1.36 %)    

Thursday, 13-Jun-2024 15:59:48 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 476.97 $ 2.57 (0.54 %)
DIA $ 386.89 $ -0.81 (-0.21 %)
SPY $ 540.15 $ 0.00 (0 %)
TLT $ 93.85 $ 1.36 (1.47 %)
GLD $ 212.97 $ -1.75 (-0.82 %)
$ 24.62
$ 24.20
$ 0.00 x 0
$ 0.00 x 0
$ 24.05 - $ 24.92
$ 11.25 - $ 56.87
441,062
na
1.46B
$ 0.30
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-10-2024 03-31-2024 10-Q
2 02-29-2024 12-31-2023 10-K
3 11-13-2023 09-30-2023 10-Q
4 08-11-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-17-2023 12-31-2022 10-K
7 11-04-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-06-2022 03-31-2022 10-Q
10 02-25-2022 12-31-2021 10-K
11 11-12-2021 09-30-2021 10-Q
12 08-13-2021 06-30-2021 10-Q
13 05-13-2021 03-31-2021 10-Q
14 03-16-2021 12-31-2020 10-K
15 11-12-2020 09-30-2020 10-Q
16 08-12-2020 06-30-2020 10-Q
17 05-13-2020 03-31-2020 10-Q
18 03-16-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 08-12-2019 06-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cantor-fitzgerald-reiterates-overweight-on-akero-therapeutics
Cantor Fitzgerald Reiterates Overweight on...
06/12/2024 16:09:56

Cantor Fitzgerald analyst Prakhar Agrawal reiterates Akero Therapeutics (NASDAQ:AKRO) with a Overweight.

wolfe-research-initiates-coverage-on-akero-therapeutics-with-outperform-rating
Wolfe Research Initiates Coverage On Akero...
06/11/2024 18:43:03

Wolfe Research analyst Andy Chen initiates coverage on Akero Therapeutics (NASDAQ:AKRO) with a Outperform rating.

akero-therapeutics-begins-phase-3-study-on-efruxifermin-for-liver-disease-treatment
Akero Therapeutics Begins Phase 3 Study on...
06/11/2024 11:05:07

Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serio...

hc-wainwright--co-reiterates-buy-on-akero-therapeutics-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Aker...
06/11/2024 10:41:06

HC Wainwright & Co. analyst Ed Arce reiterates Akero Therapeutics (NASDAQ:AKRO) with a Buy and maintains $50 price target.

reported-saturday-akero-therapeutics-presented-data-highlighting-the-efficacy-and-safety-of-efx-in-patients-with-mash-at-easl-congress
Reported Saturday, Akero Therapeutics Pres...
06/10/2024 07:44:56

A late-breaking oral presentation will feature 96-week data from HARMONY, a Phase 2b study evaluating the efficacy and safety o...

whats-going-on-with-fattly-liver-disease-focused-madrigal-pharmaceuticals-sagimet-biosciences-shares-on-wednesday
What's Going On With Fattly Liver Disease ...
06/05/2024 19:17:50

Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress ...

evercore-isi-group-maintains-outperform-on-akero-therapeutics-lowers-price-target-to-38
Evercore ISI Group Maintains Outperform on...
05/15/2024 13:17:45

Evercore ISI Group analyst Liisa Bayko maintains Akero Therapeutics (NASDAQ:AKRO) with a Outperform and lowers the price tar...

canaccord-genuity-maintains-buy-on-akero-therapeutics-lowers-price-target-to-56
Canaccord Genuity Maintains Buy on Akero T...
05/13/2024 16:35:51

Canaccord Genuity analyst Edward Nash maintains Akero Therapeutics (NASDAQ:AKRO) with a Buy and lowers the price target from...

hc-wainwright--co-reiterates-buy-on-akero-therapeutics-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Aker...
05/13/2024 10:44:16

HC Wainwright & Co. analyst Ed Arce reiterates Akero Therapeutics (NASDAQ:AKRO) with a Buy and maintains $50 price target.

akero-therapeutics-q1-eps-090-beats-095-estimate
Akero Therapeutics Q1 EPS $(0.90) Beats $(...
05/10/2024 11:15:12

Akero Therapeutics (NASDAQ:AKRO) reported quarterly losses of $(0.90) per share which beat the analyst consensus estimate of $(...

b-of-a-securities-reinstates-neutral-on-akero-therapeutics-announces-30-price-target
B of A Securities Reinstates Neutral on Ak...
04/22/2024 10:21:38

B of A Securities analyst Alexandria Hammond reinstates Akero Therapeutics (NASDAQ:AKRO) with a Neutral and announces $30 pr...

akero-therapeutics-publishes-phase-2b-symmetry-cohort-d-study-in-clinical-gastroenterology-and-hepatology
Akero Therapeutics Publishes Phase 2b SYMM...
03/07/2024 21:02:33

As reported previously, the addition of EFX to GLP-1 receptor agonist therapy had a safety and tolerability profile comparable ...

akero-therapeutics-prices-public-offering-of-11m-common-stock-at-29share
Akero Therapeutics Prices Public Offering ...
03/06/2024 07:16:58

The comnay announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a public offeri...

akero-therapeutics-shares-are-trading-lower-after-the-company-announced-a-300-million-public-offering
Akero Therapeutics shares are trading lowe...
03/05/2024 17:25:29

ubs-maintains-buy-on-akero-therapeutics-raises-price-target-to-42
UBS Maintains Buy on Akero Therapeutics, R...
03/05/2024 14:43:55

UBS analyst Eliana Merle maintains Akero Therapeutics (NASDAQ:AKRO) with a Buy and raises the price target from $39 to $42.

hc-wainwright--co-maintains-buy-on-akero-therapeutics-raises-price-target-to-50
HC Wainwright & Co. Maintains Buy on Akero...
03/05/2024 11:46:20

HC Wainwright & Co. analyst Ed Arce maintains Akero Therapeutics (NASDAQ:AKRO) with a Buy and raises the price target fr...

akero-therapeutics-begins-public-offering-of-300m-of-shares-of-its-common-stock
Akero Therapeutics Begins Public Offering ...
03/04/2024 21:23:10

All of the shares in the proposed offering are being offered by Akero Therapeutics. In addition, Akero Therapeutics intends to ...

why-bitdeer-technologies-shares-are-trading-higher-by-10-here-are-other-stocks-moving-in-mondays-mid-day-session
Why Bitdeer Technologies Shares Are Tradin...
03/04/2024 18:29:18

Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported prelimina...

10-health-care-stocks-whale-activity-in-todays-session
10 Health Care Stocks Whale Activity In To...
03/04/2024 17:35:23

akero-therapeutics-stock-is-soaring-monday---heres-why
Akero Therapeutics' Stock Is Soaring Monda...
03/04/2024 16:28:00

Akero Therapeutics success in HARMONY Phase 2b study for efruxifermin. EFX demonstrated sustained efficacy and well-tolerance, ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

AnaptysBio Inc (ANAB)